CA2312051A1 - Methylated nucleotide regulation of gene expression - Google Patents
Methylated nucleotide regulation of gene expression Download PDFInfo
- Publication number
- CA2312051A1 CA2312051A1 CA002312051A CA2312051A CA2312051A1 CA 2312051 A1 CA2312051 A1 CA 2312051A1 CA 002312051 A CA002312051 A CA 002312051A CA 2312051 A CA2312051 A CA 2312051A CA 2312051 A1 CA2312051 A1 CA 2312051A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- oligonucleotide
- complementary
- target
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 28
- 230000014493 regulation of gene expression Effects 0.000 title description 7
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 25
- 239000002773 nucleotide Substances 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims abstract description 21
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 230000000295 complement effect Effects 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 20
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 230000011987 methylation Effects 0.000 claims abstract description 9
- 238000007069 methylation reaction Methods 0.000 claims abstract description 9
- 230000001105 regulatory effect Effects 0.000 claims abstract description 9
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 5
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical group CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 22
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 108091029523 CpG island Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000003964 Histone deacetylase Human genes 0.000 description 4
- 108090000353 Histone deacetylase Proteins 0.000 description 4
- 238000011935 selective methylation Methods 0.000 description 4
- 229940104302 cytosine Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000001035 methylating effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108091006105 transcriptional corepressors Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002312051A CA2312051A1 (en) | 2000-07-13 | 2000-07-13 | Methylated nucleotide regulation of gene expression |
| AT01953714T ATE381616T1 (de) | 2000-07-13 | 2001-07-13 | Regulation der upa gen-expression durch methylierte nukleotide |
| CA002415723A CA2415723A1 (en) | 2000-07-13 | 2001-07-13 | Methylated nucleotide regulation of upa gene expression |
| ES01953714T ES2298243T3 (es) | 2000-07-13 | 2001-07-13 | Regulacion mediante nucleotidos metilados de la expresion genica de upa. |
| PCT/CA2001/001023 WO2002006462A2 (en) | 2000-07-13 | 2001-07-13 | Methylated nucleotide regulation of upa gene expression |
| DE60131973T DE60131973T2 (de) | 2000-07-13 | 2001-07-13 | Regulation der upa gen-expression durch methylierte nukleotide |
| AU7620501A AU7620501A (en) | 2000-07-13 | 2001-07-13 | Methylated nucleotide regulation of gene expression |
| US10/332,542 US7316900B2 (en) | 2000-07-13 | 2001-07-13 | Methylated nucleotide regulation of gene expression |
| JP2002512355A JP2004504028A (ja) | 2000-07-13 | 2001-07-13 | 遺伝子発現のメチル化ヌクレオチド制御 |
| AU2001276205A AU2001276205B2 (en) | 2000-07-13 | 2001-07-13 | Methylated Nucleotide Regulation of UPA Gene Expression |
| EP01953714A EP1303599B1 (en) | 2000-07-13 | 2001-07-13 | Methylated nucleotide regulation of upa gene expression |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002312051A CA2312051A1 (en) | 2000-07-13 | 2000-07-13 | Methylated nucleotide regulation of gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2312051A1 true CA2312051A1 (en) | 2002-01-13 |
Family
ID=4166531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002312051A Abandoned CA2312051A1 (en) | 2000-07-13 | 2000-07-13 | Methylated nucleotide regulation of gene expression |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7316900B2 (enExample) |
| EP (1) | EP1303599B1 (enExample) |
| JP (1) | JP2004504028A (enExample) |
| AT (1) | ATE381616T1 (enExample) |
| AU (2) | AU7620501A (enExample) |
| CA (1) | CA2312051A1 (enExample) |
| DE (1) | DE60131973T2 (enExample) |
| ES (1) | ES2298243T3 (enExample) |
| WO (1) | WO2002006462A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2589986A1 (en) * | 2004-12-07 | 2006-06-15 | Releaf | Security and storage system and method |
| FR2886946B1 (fr) * | 2005-06-09 | 2007-08-10 | Biomerieux Sa | Procede pour le diagnoctic/pronostic du cancer du sein |
| US9023819B2 (en) * | 2008-06-09 | 2015-05-05 | National Chung Cheng University | Treatment of a disease or a condition associated with aberrant gene hypomethylation by a method involving tailored epigenomic modification |
| US20100161039A1 (en) | 2008-12-23 | 2010-06-24 | Vipul Dave | Adhesion promoting temporary mask for coated surfaces |
| TWI393779B (zh) * | 2009-10-16 | 2013-04-21 | Nat Univ Chung Cheng | 用於哺乳動物細胞的三元件基因表現報導系統及其應用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5000000A (en) * | 1988-08-31 | 1991-03-19 | University Of Florida | Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes |
| US5840497A (en) | 1993-06-11 | 1998-11-24 | The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization | Method for specific silencing of genes by DNA methylation |
| US5552390A (en) * | 1993-12-09 | 1996-09-03 | The Board Of Regents Of The University Of Nebraska | Phosphorothioate inhibitors of metastatic breast cancer |
| US6017704A (en) * | 1996-06-03 | 2000-01-25 | The Johns Hopkins University School Of Medicine | Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids |
| US5874416A (en) | 1997-11-07 | 1999-02-23 | Sheikhnejad; Gholamreza | RAS antisense inhibition |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US6900016B1 (en) * | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
-
2000
- 2000-07-13 CA CA002312051A patent/CA2312051A1/en not_active Abandoned
-
2001
- 2001-07-13 US US10/332,542 patent/US7316900B2/en not_active Expired - Fee Related
- 2001-07-13 WO PCT/CA2001/001023 patent/WO2002006462A2/en not_active Ceased
- 2001-07-13 EP EP01953714A patent/EP1303599B1/en not_active Expired - Lifetime
- 2001-07-13 JP JP2002512355A patent/JP2004504028A/ja not_active Withdrawn
- 2001-07-13 AU AU7620501A patent/AU7620501A/xx active Pending
- 2001-07-13 AU AU2001276205A patent/AU2001276205B2/en not_active Ceased
- 2001-07-13 ES ES01953714T patent/ES2298243T3/es not_active Expired - Lifetime
- 2001-07-13 AT AT01953714T patent/ATE381616T1/de not_active IP Right Cessation
- 2001-07-13 DE DE60131973T patent/DE60131973T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001276205B2 (en) | 2006-02-16 |
| DE60131973D1 (de) | 2008-01-31 |
| ATE381616T1 (de) | 2008-01-15 |
| WO2002006462A2 (en) | 2002-01-24 |
| US7316900B2 (en) | 2008-01-08 |
| US20040053259A1 (en) | 2004-03-18 |
| WO2002006462A3 (en) | 2002-10-24 |
| EP1303599B1 (en) | 2007-12-19 |
| ES2298243T3 (es) | 2008-05-16 |
| JP2004504028A (ja) | 2004-02-12 |
| AU7620501A (en) | 2002-01-30 |
| DE60131973T2 (de) | 2008-12-04 |
| EP1303599A2 (en) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Czubayko et al. | Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. | |
| Gonzalgo et al. | The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines | |
| EP1695979B1 (en) | Gapped modified oligonucleotides | |
| US6184211B1 (en) | Inhibition of DNA methyltransferase | |
| Kashani-Sabet et al. | Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme | |
| Pampalakis et al. | A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition | |
| Keshet et al. | DNA methylation affects the formation of active chromatin | |
| Yu et al. | Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties | |
| US5801154A (en) | Antisense oligonucleotide modulation of multidrug resistance-associated protein | |
| Zhang et al. | Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer | |
| JPH09511125A (ja) | 腫瘍形成能抑制活性を有するアンチセンスオリゴヌクレオチド | |
| JP2002512508A (ja) | Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド | |
| Scaggiante et al. | Effect of unmodified triple helix‐forming oligodeoxyribonucleotide targeted to human multidrug‐resistance gene mdr1 in MDR cancer cells | |
| CA2312051A1 (en) | Methylated nucleotide regulation of gene expression | |
| HUT73335A (en) | Antisense oligonucleotides and methods for inhibition of the human ras genes, methods for inhibition of tumour-cells proliferation and methods for detection of activated ras-genes | |
| Ishida et al. | Genomic organization and promoter analysis of the Dnmt3b gene | |
| Rescheleit et al. | Sequence analysis and distribution of two new human cathepsin L splice variants | |
| JP2006526415A (ja) | 乳癌の診断、予後診断及び治療方法 | |
| US7368551B2 (en) | De novo DNA cytosine methyltransferase genes, polypeptides and uses thereof | |
| AU2001276205A1 (en) | Methylated Nucleotide Regulation of UPA Gene Expression | |
| US7423022B2 (en) | Nucleic acids for inhibiting hairless protein expression and methods of use thereof | |
| MAHAJNA et al. | Autoregulation of cloned human protein kinase C β and γ gene promoters in U937 cells | |
| Eastham et al. | Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line | |
| Segade et al. | Differential regulation of the murine ribosomal protein L26 gene in macrophage activation | |
| Szyf | Utilization of antisense oligonucleotides to study the role of 5-cytosine DNA methyltransferase in cellular transformation and oncogenesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |